Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
Portfolio Pulse from
Tevogen Bio (Nasdaq: TVGN) has entered into an agreement to receive up to $10 million in non-dilutive grant funding from KRHP LLC. The initial contribution is $2 million, with a potential additional $8 million contingent on future reviews. This funding will support Tevogen Bio's development of T cell therapeutics for cancer and viral infections.
January 28, 2025 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tevogen Bio has secured a grant agreement for up to $10 million in non-dilutive funding from KRHP LLC, with an initial $2 million received. This funding will aid in the development of T cell therapeutics.
The non-dilutive funding is significant for Tevogen Bio as it provides financial resources without equity dilution, supporting their R&D efforts in T cell therapeutics. This could positively impact their stock price as it strengthens their financial position and potential for product development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100